Dosisescalatiestudie van CLR 131 bij kinderen, adolescenten en jonge volwassenen met recidiverende of refractaire kwaadaardige tumoren, waaronder maar niet beperkt tot neuroblastoom, rabdomyosarcoom, Ewings-sarcoom en osteosarcoom (CLOVER-2)
Een open-label, dosisescalatie-, werkzaamheids- en veiligheidsonderzoek van CLR 131 bij kinderen, adolescenten en jongvolwassenen met geselecteerde solide tumoren, lymfoom en kwaadaardige hersentumoren
The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
Even with standard, highly toxic multimodality therapies and salvage regimen, most pediatric patients with primary metastatic or relapsed solid tumors are confronted with a poor prognosis. For these patients there is currently no accepted successful treatment regimen. There is a need for new drugs, including targeted radiopharmaceuticals, preferably with cancer-specific uptake and broad applicability for these rare pediatric malignancies.
CLR 131 is a radioiodinated therapeutic that exploits the selective uptake and retention of phospholipid ethers (PLEs) by malignant cells. Cellectar Biosciences' novel cancer-targeted small-molecule compound (CLR1404) is radiolabeled with the isotope iodine-131 (I-131). CLR 131 has demonstrated tumor selective uptake across numerous adult and pediatric cancer cell types. Therapeutic efficacy has been demonstrated in various pediatric and adult-type cancer xenograft models, confirming the ability of CLR 131 to target tumors.
Based on the critical unmet medical need for effective agents with novel mechanisms of action in relapsed pediatric cancers and initial preclinical and clinical experience with radioiodinated CLR1404, Cellectar Biosciences has chosen to assess CLR 131 in a phase 1 pediatric trial.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
New South Wales
-
Westmead, New South Wales, Australië, 2145
- Children's Hospital at Westmead
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G1X8
- Hospital for Sick Children
-
-
-
-
California
-
Palo Alto, California, Verenigde Staten, 94304
- Lucile Packard Children's Hospital
-
-
New York
-
New York, New York, Verenigde Staten, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Verenigde Staten, 27708
- Duke University
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Texas Children's Hospital
-
-
Wisconsin
-
Madison, Wisconsin, Verenigde Staten, 53792
- University of Wisconsin Hospital and Clinics
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
All Patients
- Previously confirmed (histologically or cytologically) pediatric solid tumor (e.g., neuroblastoma, sarcoma), lymphoma (including Hodgkin's lymphoma), or malignant brain tumors that are clinically or radiographically suspected to be relapsed, refractory, or recurrent for which there are no standard treatment options with curative potential. Note: patients with diffuse intrinsic pontine glioma (DIPG) may enroll without histological or cytological confirmation.
- ≥ 2 years of age and ≤ 25 years of age at time of consent/assent
- If ≥ age 16 years, Karnofsky performance status of ≥ 60. If < age 16 years, Lansky performance status ≥ 60
- Platelets ≥ 75,000/µL (last transfusion, if any, must be at least 1 week prior to study registration, and, unless deemed medically necessary, no transfusions are allowed between registration and dosing)
- Absolute neutrophil count ≥ 750/µL
- Hemoglobin ≥ 8 g/dL (last transfusion must be at least 1 week prior to study registration, and, unless deemed medically necessary, no transfusions are allowed between registration and dosing)
- Using the bedside Schwartz formula, estimated GFR (creatinine clearance) > 60 ml/min/1.73m2
- Alanine aminotransferase < 3 × ULN
- Bilirubin < 2 × ULN
- Patients who have undergone autologous or allogeneic bone marrow transplant must be at least 3 months from transplant.
- Patients enrolling at total dose levels > 30 millicurie (mCi)/m2 must have availability or ability to collect an autologous hematopoietic stem cell back-up product prior to CLR 131 administration. At minimum, 2 x 10^6/kg cryopreserved CD34+ cells must be available.
- Patient or his or her legal representative is judged by the Investigator to have the initiative and means to be compliant with the protocol.
Patients with Pediatric Solid Tumor or Lymphoma
- At least 1 measurable lesion with longest diameter of at least 10 mm. Patients with a lesion(s) that are determined to be Metaiodobenzylguanidine (MIBG) or positron emission tomography (PET) positive may be enrolled at the investigator's discretion, even if not associated with a measurable lesion of at least 10 mm. Patients with neuroblastoma who have detectable disease may enroll provided they meet the requirements of the International Neuroblastoma Response Criteria.
- Patients with known brain metastases must have completed any radiotherapy or systemic treatments for brain metastases prior to enrollment; by investigator assessment be considered stable with no new signs or symptoms for at least 1 month, and on a stable dose of steroids (unchanged for three weeks prior to registration or on a steroid tapering regimen).
Patients with Recurrent or Refractory Brain Tumors
- At least 1 measurable lesion with longest diameter of at least 10 mm on any imaging sequence.
- Patients with previously known neurological deficits must be clinically stable at time of enrollment and able to complete all study related procedures. Patients with documented or newly diagnosed neurological deficits will be enrolled at the investigator's discretion.
- If patient receives steroids for neurological symptom control, the dose must be stable (unchanged for three weeks prior to registration) or on a steroid tapering regimen. Initiation of steroids per routine care immediately prior to CLR 131 dosing is acceptable.
Exclusion Criteria:
- Patients receiving active treatment for central nervous system metastases or those that are likely to require active treatment during anticipated participation in this trial. Patients with stable brain metastases treated with steroids may enroll at the investigator's discretion
- For solid tumor and lymphoma patients only, central nervous system involvement unless previously treated with surgery, systemic therapy, or radiotherapy with the patient neurologically stable. Patients with metastatic brain tumors that have been previously treated are allowed, provided the patient is neurologically stable (determined at the investigator's discretion).
- Antitumor therapy or investigational therapy, within 2 weeks of dosing. For certain types of radiation (craniospinal, total abdominal, whole lung [spot irradiation to skull-based metastases is not considered craniospinal radiation for the purposes of this study]), at least 3 months must have elapsed. No washout is required for palliative focal radiation. NOTE: Patients participating in non-interventional clinical trials (i.e., non-drug) are allowed to participate in this trial
- Patients previously treated with iodine-131 (131I)-MIBG who have already received a cumulative I-131 dose > 54 mCi/kg or who would exceed 54 mCi/kg by participating in this trial, are not eligible.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: CLR 131
CLR 131 intravenous administration |
IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of participants with dose limiting toxicities (DLT)
Tijdsspanne: up to 64 days
|
DLT will be assessed by physical examination, vital signs, and laboratory values |
up to 64 days
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Identification of recommended phase 2 dose of CLR 131 in children, adolescents, and young adults
Tijdsspanne: until non-tolerated dose is defined; dose escalation decision made upon review of data from a complete cohort (85 days after all subjects in cohort have received infusion)
|
Dose and regimen to be used in Phase 2 trials of CLR 131 in children, adolescents, and young adults |
until non-tolerated dose is defined; dose escalation decision made upon review of data from a complete cohort (85 days after all subjects in cohort have received infusion)
|
|
Determination of preliminary antitumor activity of CLR 131 in children, adolescents, and young adults
Tijdsspanne: through Day 85
|
Response assessment per applicable criteria (e.g., Neuroblastoma Response Criteria (modified); RECIST 1.1; positron emission tomography response criteria in solid tumors (PERCIST); RANO) |
through Day 85
|
|
Determination of therapeutic activity of CLR 131 in children, adolescents, and young adults
Tijdsspanne: up to 22 days post initial infusion
|
Assessment via 131-I/CLR 131 SPECT/CT scans |
up to 22 days post initial infusion
|
|
Determination of event free survival following CLR 131 infusion in children, adolescents, and young adults
Tijdsspanne: 1 month to 5 years
|
Time from first infusion of CLR 131 until progression or recurrence of disease |
1 month to 5 years
|
|
Determination of overall survival following CLR 131 infusion in children, adolescents, and young adults
Tijdsspanne: 1 month to 5 years
|
Time from first infusion of CLR 131 until death due to any reason |
1 month to 5 years
|
|
Determine dosimetry of CLR 131 in children, adolescents, and young adults
Tijdsspanne: up to 15 days post initial infusion
|
Assessment of dosimetry via whole body planar imaging |
up to 15 days post initial infusion
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Studie directeur: Jarrod Longcor, Cellectar Biosciences
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
- lymfoom
- osteosarcoom
- Ewing-sarcoom
- ATRT
- glioblastoom
- Non-Hodgkin lymfoom
- neuroblastoom
- medulloblastoom
- hooggradig glioom
- rabdomyosarcoom
- DIPG
- sarcoom
- Wilms-tumor
- ependymoom
- PNET
- gliosarcoom
- zeldzame kanker
- Hodgkin lymfoom
- desmoplastische kleine rondceltumor
- kwaadaardige kiemceltumor
- synoviaal sarcoom
- DSRCT
- diffuus-intrinsiek ponsglioom
- atypische teratoïde rhabdoïde tumor
- primitieve neuroectodermale tumor
- gliomatose cerebri
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Mannelijke urogenitale ziekten
- Nier Ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Genetische ziekten, aangeboren
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Neoplasmata, glandulair en epitheel
- Lymfatische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Urologische neoplasmata
- Astrocytoom
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Neoplasmata van het zenuwstelsel
- Nierneoplasmata
- Neoplastische syndromen, erfelijk
- Neoplasmata, bindweefsel en zacht weefsel
- Neuro-ectodermale tumoren, primitief, perifeer
- Neoplasmata, botweefsel
- Neoplasmata, bindweefsel
- Neoplasmata van het centrale zenuwstelsel
- Neoplasmata, spierweefsel
- Neoplasmata, complex en gemengd
- Myosarcoom
- Hersenneoplasmata
- Hersenstamneoplasmata
- Infratentoriale neoplasmata
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Hemische en lymfatische ziekten
- Diffuus intrinsiek ponsglioom
- Lymfoom
- Glioblastoom
- Glioom
- Neuroblastoom
- Sarcoom, Ewing
- Lymfoom, non-Hodgkin
- Sarcoom
- Ziekte van Hodgkin
- Sarcoom, synoviaal
- Rhabdomyosarcoom
- Gliosarcoom
- Osteosarcoom
- Ependymoom
- Medulloblastoom
- Neuro-ectodermale tumoren, primitief
- Wilms-tumor
- Rhabdoïde tumor
- Desmoplastische kleine ronde celtumor
- Neoplasmata, neuro-epitheliaal
- CLR1404
Andere studie-ID-nummers
Andere studie-ID-nummers
- DCL-17-001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .